These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 12007850

  • 1. Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000: results from The Surveillance Network (TSN) Database-USA.
    Karlowsky JA, Jones ME, Mayfield DC, Thornsberry C, Sahm DF.
    Int J Antimicrob Agents; 2002 May; 19(5):413-26. PubMed ID: 12007850
    [Abstract] [Full Text] [Related]

  • 2. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN, Sader HS, Fritsche TR, Pottumarthy S.
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [Abstract] [Full Text] [Related]

  • 3. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
    Morfin-Otero R, Noriega ER, Dowzicky MJ.
    Ann Clin Microbiol Antimicrob; 2015 Dec 15; 14():53. PubMed ID: 26667651
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Diagn Microbiol Infect Dis; 2001 Dec 15; 40(1-2):51-7. PubMed ID: 11448564
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
    Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PR, Walkty AJ, Hoban DJ, Zhanel GG.
    Antimicrob Agents Chemother; 2013 Nov 15; 57(11):5600-11. PubMed ID: 23979759
    [Abstract] [Full Text] [Related]

  • 6. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
    Jones RN, Kirby JT, Rhomberg PR.
    Diagn Microbiol Infect Dis; 2008 Jun 15; 61(2):203-13. PubMed ID: 18329835
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.
    Karlowsky JA, Adam HJ, Decorby MR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG.
    Antimicrob Agents Chemother; 2011 Jun 15; 55(6):2837-46. PubMed ID: 21402844
    [Abstract] [Full Text] [Related]

  • 8. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J, Oguri T, Hiramatsu N, Akiyama K, Koyama T.
    Jpn J Antibiot; 2002 Feb 15; 55(1):22-60. PubMed ID: 11977920
    [Abstract] [Full Text] [Related]

  • 9. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network.
    Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF.
    Int J Antimicrob Agents; 2002 Jan 15; 19(1):21-31. PubMed ID: 11814764
    [Abstract] [Full Text] [Related]

  • 10. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ, Park CH.
    Clin Ther; 2008 Nov 15; 30(11):2040-50. PubMed ID: 19108792
    [Abstract] [Full Text] [Related]

  • 11. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
    Borbone S, Cascone C, Santagati M, Mezzatesta ML, Stefani S.
    Int J Antimicrob Agents; 2006 Nov 15; 28(5):396-401. PubMed ID: 17045463
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
    Huband MD, Pfaller MA, Shortridge D, Flamm RK.
    J Glob Antimicrob Resist; 2019 Dec 15; 19():56-63. PubMed ID: 30825698
    [Abstract] [Full Text] [Related]

  • 17. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy.
    Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D.
    Int J Antimicrob Agents; 2003 Oct 15; 22(4):406-19. PubMed ID: 14522104
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM, Aranza MK, Shah D, Sahm DF.
    J Antimicrob Chemother; 2008 Mar 15; 61(3):595-602. PubMed ID: 18218646
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.